

320 Wakara Way Salt Lake City, UT 84108 www.myriad.com



Fast Facts

Founders: Dennis Farrar, Walter Gilbert, Kevin Kimberlin, Peter Meldrum, Mark Skolnick

Date Founded: 1991 Employees: 1,169

Headquarters: Salt Lake City, UT

Revenue: \$496,010,000 (FY 2012) University: University of Utah

Federal Funding Agency: National Institutes of Health (National Human Genome Research Institute;

National Center for Research Resources), Department of Defense (U.S. Army)

Initial Research Funding: \$25M

Myriad was formed in 1991 as one of the first genomic companies dedicated to examining the role genes play in human disease. The company is focused on revolutionizing patient care through the development and marketing of transformative tests and novel molecular diagnostic products that address pressing clinical needs across multiple medical specialties. Over the last 20 years, Myriad has invested heavily in the education of patients and health care providers on the role genes and their related proteins play in disease. Almost one million patients have already benefited from Myriad's informative testing, which helps physicians better manage their health care.

Myriad's discoveries include the *BRCA1* and *BRCA2* hereditary breast and ovarian cancer genes; the *p16* cell cycle control gene that increases the risk of developing a variety of cancers, notably melanoma; the *PTEN* tumor suppressor gene that is involved in the development of many cancers; and the *ELAC2* prostate cancer gene.

The Story Behind the Company

The formation and development of Myriad stems from research at the University of Utah, which began in 1975 and was led by Mark Skolnick, then a professor in the Department of Medical Informatics. Much of the research surrounded the discovery of BRCA1 and BRCA2, which are both hereditary breast and ovarian cancer genes.

The BRCA1 and BRCA2 research, as well as significant other work related to mapping, sequencing and understanding the relationship between the genes and disease, culminated in the formation of Myriad. Myriad was created to commercially develop genetic tests developed at the University of Utah.

From January 1975 to September 1995, researchers at the University of Utah received \$25 million in combined funding from the National Institutes of Health, through the National Cancer Institute, National Human Genome Research Institute and the National Center for Research Resources, and the U.S. Army.